James Panek
Director/Board Member bij SUTRO BIOPHARMA, INC.
Vermogen: - $ op 31-03-2024
Profiel
James P.
Panek is an Independent Director at Sutro Biopharma, Inc. and the Chief Operating Officer at CHO Plus, Inc. He previously served as the Chairman & Co-Chief Executive Officer at Celltrion, Inc. from 2002 to 2006.
From 2007 to 2011, he was the President, Chief Executive Officer, CFO & Director at Diadexus, Inc. Prior to that, he held the positions of President, Chief Financial Officer, CAO & Director at VaxGen, Inc. from 2002 to 2010.
He also served as a Director at diaDexus, Inc. and held the role of Senior Vice President-Product Operations at Genentech, Inc. from 1982 to 2001.
Mr. Panek completed his undergraduate and graduate degrees at the University of Michigan.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
-.--% | 08-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van James Panek
| Bedrijven | Functie | Begin |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Director/Board Member | 07-01-2020 |
| Cho Plus, Inc. | Chief Operating Officer | - |
Eerdere bekende functies van James Panek
| Bedrijven | Functie | Einde |
|---|---|---|
| DIADEXUS, INC. | Chief Executive Officer | 01-01-2011 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Director/Board Member | 01-11-2010 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01-01-2010 |
| CELLTRION, INC. | Chief Executive Officer | 01-01-2006 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01-01-2001 |
Opleiding van James Panek
| University of Michigan | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| CELLTRION, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
| Cho Plus, Inc. |
